Stocks in Action USA: Ionis Pharmaceuticals, PepsiCo, and Newmont.
Reading Time: 3 minutes
Ionis Pharmaceuticals (IONS) – Olezarsen Achieves Breakthrough Success in Phase 3 Trials for Severe Hypertriglyceridemia! Ionis Pharmaceuticals has announced positive topline results from the Phase 3 trials CORE and CORE2 with Olezarsen in patients with severe hypertriglyceridemia (sHTG). The treatment reduced fasting triglycerides compared to placebo by up to 72% and, for the first time in this indication, reduced acute pancreatitis events by 85%. The studies confirmed a favorable safety and tolerability profile, with side effects being mostly...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
